6ets Citations

Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.

ChemMedChem 14 1828-1839 (2019)
Related entries: 6etg, 6ett, 6etu, 6etv, 6etw

Cited: 6 times
EuropePMC logo PMID: 31475772

Abstract

Human histone demethylases are known to play an important role in the development of several tumor types. Consequently, they have emerged as important medical targets for the treatment of human cancer. Herein, structural studies on tetrazolylhydrazide inhibitors as a new scaffold for a certain class of histone demethylases, the JmjC proteins, are reported. A series of compounds are structurally described and their respective binding modes to the KDM4D protein, which serves as a high-resolution model to represent the KDM4 subfamily in crystallographic studies, are examined. Similar to previously reported inhibitors, the compounds described herein are competitors for the natural KDM4 cofactor, 2-oxoglutarate. The tetrazolylhydrazide scaffold fills an important gap in KDM4 inhibition and newly described, detailed interactions of inhibitor moieties pave the way to the development of compounds with high target-binding affinity and increased membrane permeability, at the same time.

Reviews - 6ets mentioned but not cited (1)

  1. Recent Advances with KDM4 Inhibitors and Potential Applications. Wu Q, Young B, Wang Y, Davidoff AM, Rankovic Z, Yang J. J Med Chem 65 9564-9579 (2022)

Articles - 6ets mentioned but not cited (1)

  1. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases. Małecki PH, Rüger N, Roatsch M, Krylova O, Link A, Jung M, Heinemann U, Weiss MS. ChemMedChem 14 1828-1839 (2019)


Articles citing this publication (4)

  1. Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models. Brai A, Riva V, Clementi L, Falsitta L, Zamperini C, Sinigiani V, Festuccia C, Sabetta S, Aiello D, Roselli C, Garbelli A, Trivisani CI, Maccari L, Bugli F, Sanguinetti M, Calandro P, Chiariello M, Quaranta P, Botta L, Angelucci A, Maga G, Botta M. Cancers (Basel) 13 5569 (2021)
  2. Computational Prediction of the Binding Pose of Metal-Binding Pharmacophores. Karges J, Stokes RW, Cohen SM. ACS Med Chem Lett 13 428-435 (2022)
  3. Transcriptomic and Drug Discovery Analyses Reveal Natural Compounds Targeting the KDM4 Subfamily as Promising Adjuvant Treatments in Cancer. Del Moral-Morales A, Salgado-Albarrán M, Ortiz-Gutiérrez E, Pérez-Hernández G, Soto-Reyes E. Front Genet 13 860924 (2022)
  4. KDM4 Demethylases: Structure, Function, and Inhibitors. Jiang Y, Liu L, Yang ZQ. Adv Exp Med Biol 1433 87-111 (2023)